ABVX:EPA
Abivax SA
€ 77.15
arrow_downward
-0.64%(-0.50) Siku 1
6 Nov, 17:36:06 GMT +1 · EUR
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya ABVX...
Fungua
€ 74.45
Juu
€ 77.15
Chini
€ 73.80
Mtaji wa soko
6.84B
Wastani wa kiasi cha mauzo
elfu 111.44
Kiasi cha mauzo ya hisa
elfu 161.37
Juu kwa wiki 52
€ 139.00
Chini kwa wiki 52
€ 60.45
EPS
-€ 5.20
Hisa za wawekezaji
87.55M
Idadi ya wafanyakazi
98
Fungua
€ 74.45
Juu
€ 77.15
Chini
€ 73.80
Mtaji wa soko
6.84B
Wastani wa kiasi cha mauzo
elfu 111.44
Kiasi cha mauzo ya hisa
elfu 161.37
Juu kwa wiki 52
€ 139.00
Chini kwa wiki 52
€ 60.45
EPS
-€ 5.20
Hisa za wawekezaji
87.55M
Idadi ya wafanyakazi
98
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Trefis
·
saa 2 zilizopita
4 S&P 500 Stocks Just Made New 52-Week Lows
Reuters Connect
·
saa 11 zilizopita
A screen displays the Dow Jones Industrial Average after the closing bell on the floor of the NYSE in New York
qz.com
·
saa 17 zilizopita
Magnificent Seven stocks and their share of the S&P 500
StoneX
·
siku 1 iliyopita
S&P 500 Forecast: SPX rebounds after strong NFP led by tech
Wasifu
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Kuhusu Abivax SA
Afisa Mkuu Mtendaji (CEO)Marc de Garidel | Hartmut J. Ehrlich
Wafanyakazi98
Lilianzishwa4 Des 2013
Makao makuu-
SektaHealth Care
Sekta-
Tovutiabivax.com